Estrogen receptor (ER) positive/HER2-negative breast cancer (BC) comprises 75–80% of all BC and this fraction is even higher (> 90%) in invasive lobular carcinoma (ILC) [1, 2]. This evidence concerns the gene ESR1 and breast carcinoma.